• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

How to Slow CKD Progression: Treatment Essentials for Primary Care


Most patients with chronic kidney disease are treated in primary care where the primary goal is twofold: slow progression and prevent complications. Find essentials of both, here.

Patients with chronic kidney disease (CKD) are treated with the goals of slowing progressive loss of kidney function and preventing or managing complications.

Essential elements of treatment include diabetes and hypertension management and reducing risk of cardiovascular disease. Guidance specific to primary care physicians, who treat the majority of patients, comes from the National Kidney Disease Program and the Kidney Disease Outcomes Quality Initiative and is summarized in the following slides.

For additional articles in this collection on chronic kidney disease, please see:

Chronic Kidney Disease Diagnosis in Primary Care

Defining Chronic Kidney Disease in Primary Care: Management, Complications, Risk, Referral

Finerenone Shows Potential to Delay Afib Onset in Patients with CKD, T2D

Diabetes Management in CKD: 10 Top Takeaways from KDIGO 2020

SGLT2 Inhibitors Enter Vast Treatment Void for High-risk CKD Patients

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.